Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 843-850

  Gordon, M S ^a   Margolin, K ^a   Talpaz, M ^a   Sledge G W , Jr ^a   Holmgren, E ^a   Benjamin, R ^a   Stalter, S ^a   Shak, S ^a   Adelman, D C ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ANTIBODY; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035253739     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.843     Document Type: Article

References (25)

1. Consequences of angiogenesis for tumor progression, metastasis, and cancer therapy
2. The biology of vascular endothelial growth factor
3. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
4. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb
5. Molecular and biological properties of the vascular endothelial cell growth factor family of proteins
6. Serum vascular endothelial growth factor is often elevated in disseminated cancer
7. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
8. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
9. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
10. Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
11. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice
12. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies
13. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
14. Intracranial metastases of hepatocellular carcinoma: CT and MRI
15. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma
16. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin, in human primary breast cancer and its relation to angiogenesis
17. Regulation of vascular endothelial growth factor by the product of the VHL tumor suppressor gene
18. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis
19. A phase I/II study of SU5416 in combination with 5-fluorouracil/leucovorin in patients with metastatic colorectal cancer
20. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized antibody to vascular endothelial growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
21. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
22. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis
23. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
24. Antiangiogenic therapy of a recurrent giant cell tumor with interferon-alfa-2a
25. Successful treatment of an angiogenic disease